Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leading Tuberculosis Experts Explore Shortcomings in Current Immigrant TB Screening Policy

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
Improved immigration policy and replacement of century-old diagnostic tests have potential to significantly reduce cases of latent tuberculosis in the UK.

Leading scientists and experts in the field of tuberculosis (TB) are meeting today to discuss how to improve national prevention strategies for the control of TB. UK is one of few countries in Western Europe which has seen an increase in the number of active TB cases in recent years. The group, chaired by Professor Peter Davies, Consultant Chest Physician at Liverpool Heart and Chest Hospital and Dr Onn Min Kon, Consultant Respiratory Physician at St Mary’s Hospital, is expected to acknowledge recent findings that current UK immigrant screening procedures miss more than 70 per cent of latent TB infection and develop a consensus on how replacing current diagnostic tools with new cutting-edge technology, can reduce disease burden and cost.

TB remains one of the most contagious and prevalent diseases in the world, with approximately nine million active cases globally. It is estimated that there are also about two billion people around the world infected with latent, or inactive, TB. Research shows that in people with latent TB, preventative treatment can reduce the risk of developing active TB by as much as 90 per cent – demonstrating the importance of identifying and treating latent disease.

In Britain, cases of TB increased by almost 50 per cent between 1989 and 2009, with 9,040 cases reported in the UK in 2009; in 2011, TB reached its highest peak in 30 years. Foreign-born individuals account for nearly three quarters of the country’s TB cases.

“A significant proportion of active TB cases in the UK stem from immigrants carrying latent TB, whose infections are ‘reactivated’ at some point after they arrive in this country” said meeting co-chair Professor Peter Davies, Consultant Chest Physician at Liverpool Heart and Chest Hospital. “Compounding this is that the diagnostic test that has traditionally been used for identifying latent TB infection is more than 100 years old, and is often inaccurate. Clearly, this is a two-pronged problem that requires a two-pronged solution – we need clearer strategies for testing for latent disease among immigrants, and better diagnostic tests to enable us to do so.”

The tuberculin skin test (TST), the tool traditionally used to identify latent TB infection, is the oldest diagnostic test in medical practice, and is widely acknowledged to have shortcomings in relation to specificity and is more difficult to administer in practice. To combat the lack of an acceptable test for latent TB, new, highly-specific and faster tests have been developed, known as interferon-gamma release assays (IGRAs). Already widely used in US, Europe and Asia, IGRAs have demonstrated significant value in both accurate diagnosis of the disease and cost-effectiveness of the tests, and data show that this cost-effectiveness would be replicated should IGRAs be used in the UK.

“We urgently need to stem the tide of rising TB cases in the UK,” said meeting co-chair Dr Onn Min Kon, Consultant Respiratory Physician at St Mary’s Hospital. “This is not a problem that can be tackled by healthcare professionals alone – it needs to be a joint effort with policy and society. We look forward to an informative discussion about how best to tackle the influx of TB infection stemming from the immigrant community, and how to incorporate the new, and much more efficient and effective, IGRA testing into our efforts to screen for and prevent the spread of TB.”

QIAGEN is sponsoring this symposium as part of their ongoing commitment to the field of TB.

QIAGEN markets the QuantiFERON-TB Gold, the leading test for detection of latent TB, which has worldwide approvals and is recommended in several national and international guidelines.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qiagen Completes Exiqon Tender Offer
Transaction will enhance leadership position in RNA solutions from Sample to Insight.
Friday, June 24, 2016
Qiagen Amends Terms to Exiqon Acquisition Offer Again
Acceptance rate lowered to 89.20% of share capital and voting rights to reflect possible effect of warrants.
Thursday, June 09, 2016
QIAGEN Partners to Develop Predictive Tests in Oncology
Collaboration with Therawis addresses unmet need to guide clinical decisions in breast cancer.
Friday, May 27, 2016
Qiagen Bids $100M to Acquire Exiqon
Transaction will expand leadership position in RNA technologies.
Thursday, March 31, 2016
Qiagen and 10x Genomics to Enter Into Co-Marketing and Co-Development Collaboration
Company has announced that the multi-phase collaboration to advance next-generation sequencing, single-cell biology, and bioinformatics Sample to Insight solutions.
Wednesday, February 17, 2016
QIAGEN,Biotype Diagnostics Form Partnership
New “Biotype Innovation” to develop workflows for personalized health-care and other applications based on QIAGEN’s ModaPlex platform.
Monday, June 29, 2015
Hitachi High-Technologies, QIAGEN Collaborate
Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Thursday, June 18, 2015
QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN, Astellas CDx Partnership
Collaboration provides options for collaboration across therapeutic areas, sample types and testing technologies.
Thursday, October 30, 2014
QIAGEN, BGI Tech Database Agreement
BGI Tech will provide services to the Greater China market with the widely used HGMD literature source.
Friday, August 01, 2014
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!